Home Tags Pembrolizumab

Tag: pembrolizumab

Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

FDA Accepts Supplemental Biologics License Applications for Pembrolizumab

Peter Hofland, Ph.D -

Pembrolizumab as 1st-line Therapy for Merkel Cell Carcinoma Shows Improved Survival

Peter Hofland, Ph.D -

Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma ...

Danielle Garcia -

Pembrolizumab Improves Survival of Patients with Metastatic or Recurrent Head and...

Peter Hofland, Ph.D -

Nivolumab + Low-dose Ipilimumab may be First Line Treatment in Some...

Sonia Portillo -

Combination of DKN-01 and Pembrolizumab in Esophagogastric Cancer Shows Promise

Peter Hofland, Ph.D -

Tumor Regressions Observed in Lymphoma Patients Treated with DPX-Survivac + Pembrolizumab

Peter Hofland, Ph.D -

New Immunotherapy Combination Tolerable, Effective in Patients with Advanced Kidney Cancer

Peter Hofland, Ph.D -

Combination of Pembrolizumab + Trastuzumab

Peter Hofland, Ph.D -

Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...

Peter Hofland, Ph.D -
12Page 1 of 2

LATEST

© 2019 Sunvalley Communication, LLC. All Rights Reserved.